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SCIENTIFIC OPINION  
Scientific Opinion on the safety and efficacy of Ronozyme RumiStar 
(alpha-amylase) as a feed additive for dairy cows
1, 2 
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
3, 4 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Ronozyme RumiStar is a feed additive in which the declared enzymatic activity is alpha-amylase. It is produced 
by a genetically modified Bacillus licheniformis strain. The final enzyme preparations contain no cultivable 
production organisms or recombinant DNA. Based on the results of a tolerance trial provided by the applicant, it 
was  concluded  that  Ronozyme  RumiStar  is  safe  for  use  in  dairy  cows  at  the  maximum  proposed  dose 
(400 KNU/kg dry matter of total daily ration) when administered in a total mixed ration with a starch level 
below 30 %. Based on the results of two in vitro genotoxicity studies and a subchronic oral toxicity rat study, it 
is concluded that no concerns for consumer safety arise from the use of Ronozyme RumiStar as a feed additive 
for dairy cows. Ronozyme RumiStar is not considered to be irritant to human skin or eye. The additive  is 
considered to be a potential skin and respiratory sensitiser. The active substance of Ronozyme RumiStar is a 
protein  and  as  such  will  be  degraded/inactivated  during  passage  through  the  digestive  tract  of  animals. 
Therefore, no risks to the environment are expected and no further environmental risk assessment is required. 
From five efficacy studies provided by the applicant, significant positive effects were observed in only one trial 
in  which  an  energy-deficient  diet  was  used.  Therefore,  no  conclusions  can  be  drawn  on  the  efficacy  of 
Ronozyme RumiStar in dairy cows. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following  a  request  from  the  European  Commission,  the  Panel  on  Additives  and  Products  or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and 
efficacy of Ronozyme RumiStar (alpha-amylase) as a feed additive for dairy cows. 
Ronozyme RumiStar is produced by a genetically modified Bacillus licheniformis strain. The final 
enzyme preparations contain no cultivable production organisms or recombinant DNA, above the 
limits of detection. The products do not have antimicrobial activity. 
The different formulations of the additive are considered to be equivalent when used at the same dose, 
taking into account the tolerance and efficacy for the target species. 
Based on the results obtained in the tolerance trial provided by the applicant, the FEEDAP Panel 
concludes that Ronozyme RumiStar is safe for use in dairy cows at the maximum proposed dose 
(400 KNU/kg dry matter of total daily ration) when administered in a total mixed ration with a starch 
level below 30 %. 
Based on the results of two in vitro genotoxicity studies and a subchronic oral toxicity rat study, it is 
concluded that no concerns for consumer safety arise from the use of Ronozyme RumiStar as a feed 
additive for dairy cows. 
Ronozyme RumiStar is not considered to be irritant to human skin or eye based on the results of tests 
in rabbits. The additive is considered to be a potential skin and respiratory sensitiser. 
The active substance of Ronozyme RumiStar is a protein and as such will be degraded/inactivated 
during passage through the digestive tract of animals. Therefore, no risks  to the environment are 
expected and no further environmental risk assessment is required. 
From five efficacy studies provided by the applicant, significant positive effects were observed in 
only one trial in which an energy-deficient diet was used. Therefore, no conclusions can be drawn on 
the efficacy of Ronozyme RumiStar in dairy cows. Ronozyme RumiStar for dairy cows 
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BACKGROUND  
Regulation  (EC)  No  1831/2003
5  establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7.  
The European Commission received  a request from  the company  DSM Nutritional Products
6  for 
authorisation of the product  Ronozyme RumiStar, alpha-amylase, when used as a feed additive for 
dairy cows  (category:  zootechnical additive; functional group:  digestibility enhancers)  under the 
conditions mentioned in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application to the European Food Safety Authority (EFSA) as an application under Article 4(1) 
(authorisation of a feed additive or new use  of a feed additive). EFSA received directly from the 
applicant  the  technical  dossier  in  support  of  this  application.
7  According  to  Article  8  of  that 
Regulation, EFSA, after verifying the particulars and documents submitted by the applicant, shall 
undertake an assessment in order to determine whether the feed additive complies with the conditions 
laid down in Article 5. The particulars and documents in support of the application were considered 
valid by EFSA as of 7 June 2010. 
The additive Ronozyme RumiStar CT/L is a preparation of alpha-amylase produced by a genetically 
modified strain of  Bacillus  licheniformis  (DSM  21564).  This  product  has  not  been  previously 
authorised in the European Union. 
TERMS OF REFERENCE  
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animals, consumer, user and the environment and the efficacy of the product 
Ronozyme RumiStar (alpha-amylase), when used under the conditions described in Table 1. 
                                                       
5   Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
6   DSM Nutritional Products, represented in EU by DSM Nutritional Products Sp. Z o.o. Poland, Tarczynska 113, 96-320 
Mszczonow, Poland. 
7   EFSA Dossier reference: FAD-2010-0009. Ronozyme RumiStar for dairy cows 
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Table 1:   Description and conditions of use of the additive as proposed by the applicant 
Additive   RONOZYME RumiStar 
Registration number/EC 
No/No (if appropriate)  To be established 
Category(-ies) of additive  Zootechnical additive 
Functional group(s) of additive  Digestibility enhancers 
 
Description 
Composition, description  Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Coated Thermo tolerant 
granulate (CT): alpha-amylase 
160 KNU/g 
Aqueous Liquid (L): alpha-
amylase 240 KNU/g 
Alpha-amylase 
(IUB  No 
3.2.1.1) 
produced  by 
Bacillus 
licheniformis 
(DSM 21564) 
Solid- min. 160 KNU/g 
Liquid-  min.  240 
KNU/g 
Colorimetric method:alpha-
amylase  release    yellow 
colored p-nitrophenol  from 
ethylidene-G7-p-
nitrophenyl-
maltoheptaoside. 
 
Trade name (if appropriate)  Solid form: RONOZYME RumiStar (CT) 
Liquid form: RONOZYME RumiStar (L) 
Name of the holder of 
authorisation (if appropriate)  DSM Nutritional Products 
 
Conditions of use 
Species  or 
category  of 
animal 
Maximum 
Age 
Minimum content  Maximum content  Withdrawal 
period 
(if appropriate)  mg/kg of complete feedingstuffs 
Dairy cows  -  300  -  - 
 
Other provisions and additional requirements for the labeling 
Specific conditions or restrictions for 
use (if appropriate) 
Recommended dose per kg of complete  feedingstuff: Dairy cows 
300-–400 KNU 
Specific conditions or restrictions for 
handling (if appropriate)   
Post-market monitoring  
(if appropriate) 
No additional requirements further to the need for traceability and 
recall procedures established by Regulation No 178/2002. 
Specific conditions for use in 
complementary feedingstuffs  
(if appropriate) 
- 
 
Maximum Residue Limit (MRL) (if appropriate) 
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues 
-  -  -  - Ronozyme RumiStar for dairy cows 
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ASSESSMENT 
1.  Introduction 
The  additive  Ronozyme  RumiStar  is  a  preparation  of  alpha-amylase  produced  by  a  genetically 
modified strain of Bacillus licheniformis (DSM 21564). It is intended for use as a zootechnical feed 
additive  (functional  group:  digestibility  enhancers)  for  dairy  cows.  It  has  not  been  previously 
authorised in the European Union. 
2.  Characterisation 
2.1.  Characterisation of the additive 
The additive is available in solid (Ronozyme RumiStar 160 (CT)) and liquid (Ronozyme RumiStar 
240 (L)) forms. 
Ronozyme RumiStar 160 (CT) is a white, fine-granular solid that contains, on a dry matter basis 
(DM): 1.5 % alpha-amylase enzyme concentrate, 56 % sodium sulphate, 14 % calcium carbonate or 
kaolin, 11  % dextrin and sucrose, 7.8 % cellulose, 3.5 % sodium chloride, 3.4 % hydrogenated palm 
oil and 0.9 % sodium thiosulphate (all food or feed grade ingredients). The minimum declared enzyme 
activity of 160 KNU
8/g was confirmed in five batches (mean value of 186 KNU/g) with a coefficient 
of variation (CV) of 3.2 %.
9, 10 A study of the particle size distribution (three batches) showed that 
43 % of the particles are greater than 850 µm in diameter and no particles are below 250 µm. This 
formulation has a low dusting potential in the Stauber–Heubach test (10.7 mg/25 g).
11 
Ronozyme RumiStar 240 (L) is a brown liquid that contains 1.8 % of the liquid alpha-amylase enzyme 
concentrate (expressed as dry matter (DM)), 32 % sucrose,
12 14 % sodium chloride, 0.5 % methionine 
and  52 %  water  (all  food  or  feed-grade  ingredients).  The  minimum  declared  enzyme  activity  of 
240 KNU/g  product  was  confirmed  in  five  batches  (mean  value  of  263 KNU/g)  with  a  CV  of 
1.1  %.
13,14 This form shows a density of 1.23–1.26 kg/L and a viscosity of 8 mPa s at 10 °C. 
The final formulations of Ronozyme RumiStar conform to the Joint FAO/WHO Expert Committee on 
Food Additives (FAO, 2001) specifications for heavy metals and arsenic and for microbial counts 
(total coliforms, Salmonella, Escherichia coli) (confirmed in three batches of each formulation).
15 
Absence of the production strain  and antibiotic activity was demonstrated in three batches of the 
enzyme concentrate that were used to prepare the final formulations.
16 
2.2.  Characterisation of the active substance
17 
2.2.1.  Information relating to the genetically modified microorganism 
The dossier contains detailed information on the recipient microorganism (including aspects on the 
safety of the strain lineage), the donor organism and the genetic modification process.  
                                                       
8  1 KNU is the amount of enzyme that releases 6 μmol p-nitrophenol per minute from 1.86 mM ethylidene-G7-p-
nitrophenyl-maltoheptaoside at pH 7.0 and 37 °C. 
9  Technical dossier/Section II/Annex_3. 
10   Supplementary information November 2011/Annex 1. 
11   Technical dossier/Section II/Annex 2-22. 
12   Supplementary information November 2011. 
13   Technical dossier/Section II/Annex 3. 
14   Supplementary information November 2011/Annex 2. 
15   Technical dossier/Section II/Annex 2-2 and Annex 2-3. 
16   Technical dossier/Section II/Annex2-21. 
17   This section has been edited following the provisions of Article 8(6) and 18 of Regulation (EC) No 1831/2003. Ronozyme RumiStar for dairy cows 
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2.2.2.  Information relating to the production process 
The alpha-amylase is produced in a contained, submerged fed-batch, pure culture fermentation and 
conventional process controls are in place. 
The production strain could not be detected in three liquid and three solid batches of the enzyme 
concentrate before formulation.
18, 19No recombinant DNA was detected in three batches of the liquid 
final  product  by  polymerase  chain  reaction  (PCR)  above  the  limit  of  detection  provided  by  the 
applicant.
20, 21 
2.3.  Physicochemical and technological properties of the additive 
2.3.1.  Shelf-life of the additive 
The shelf-life of the solid and liquid forms of the additive was measured in three batches each.
22 The 
samples were kept in closed vials for up to 12 mon ths at different temperatures: –18, 10, 25, 35 and 
40 °C. Mean recoveries for the solid form were expressed as a percentage of the activity of the sample 
kept at –18 °C at the same time point. The results showed that no loss of activity was experienced 
when samples were stored at up to 25 °C and values remained greater than 70 % following storage at 
40 °C for 12 months. The stability of the batches was also tested when kept for one month in an open 
vial at 40 °C and 60  % relative humidity; mean recoveries were 86 %. Similar results were obtained 
with the liquid form of the additive.
23 
2.3.2.  Stability of the additive in premixtures 
The stability of the solid form when added to premixtures was studied in three batches when mixed to 
two different complete premixtures for dairy cattle at a level of 30 000 KNU/kg premixture and kept at 
25 °C. Mean recoveries were greater than 80 % and 74 % after 3 and 6 months, regardless of the type 
of premixture. 
2.3.3.  Stability of the additive in feedingstuffs 
The stability of Ronozyme
 RumiStar 160 (CT) added to mash feed (wheat, maize, wheat bran and 
soybean meal) at an intended dose of 300 KNU/kg was studied for three batches of the product.
24 No 
losses were found after three months’ storage at 25 °C. 
The stability of Ronozyme
 RumiStar 160 (CT) during pelleting (at 75 or 85 °C) and storage of pelleted 
feed was tested for three batches of the additive. The enzyme activity was measured in the initial mash 
form and in the pelleted feed immediately after pelleting and after 3 months’ storage at 25 °C. The 
mash feed was supplemented with additive to an intended dose of 300 KNU/kg. Recoveries averaged 
76 % of the initial value after pelleting at 75 °C and 90 % after pelleting at 85 °C. After three months, 
recovery as a percentage of the values found in mash feed was 80 % and 86 % for samples pelleted at 
75 and 85 °C, respectively (no activity was lost after three months in the pelleted feed). 
The stability of Ronozyme
 RumiStar 240 (L) sprayed onto pelleted feed (wheat, maize, wheat bran and 
soybean meal) at an intended dose of 300 KNU/kg was studied in three batches of the product.
25 No 
losses were seen when pelleted feed was subsequently stored for 3 months at 25 °C. 
                                                       
18   Technical dossier/Annexes Section II/Annex 2-21. 
19   Technical dossier/Supplementary information November 2011/Annex 9. 
20   Technical dossier/Section II/Annex 2-29. 
21   Technical dossier/Supplementary information November 2011/Annex 10. 
22   Technical dossier/Section II/Annex 2-46. 
23   Technical dossier/Section II/Annex 2-47. 
24   Technical dossier/Section II/Annex 2-22. 
25   Technical dossier/Section II/Annex 2-22. Ronozyme RumiStar for dairy cows 
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2.3.4.  Homogeneity of the additive 
Homogeneity of the solid form (Ronozyme RumiStar 160 (CT)) was determined in six subsamples 
from three batches in premixtures and complete feed. The results showed a CV of 5.1 % (2.9–6.4 %) 
and 2.8 % (1.0–3. %9), respectively. Homogeneity of the liquid form (Ronozyme RumiStar 240 (L)) 
was determined in six subsamples from three batches in complete feed and showed a CV of 3.4 % 
(2.0–4.7 %).
26 
2.4.  Conditions of use 
The additive is intended to be used in lactating dairy cows fed a plant-based diet of “medium starch 
content”. The minimum recommended dose is 300 KNU/kg and the maximum is 400 KNU/kg DM 
complete feed (total mixed ration (TMR), including concentrates and forages). The additive can either 
be added to the concentrate or sprayed onto the TMR. 
2.5.  Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
EFSA has verified the EURL report as it relates to the methods used for the control of the active 
substance in animal feed. The Executive Summary of the EURL report can be found in the appendix. 
3.  Safety 
3.1.  Safety aspects of the genetic modification
27 
The recipient organism is considered to be safe. The genetic modification does not trigger a safety 
concern.  The  applicant  provided  sufficient  information  that  neither  the  production  strain  nor  the 
recombinant genes is present in the final products, given the limits of detection provided. Evaluation 
of the safety of the product is covered by the studies of mutagenicity, animal feeding trials and studies 
on antimicrobials. 
3.2.  Safety for the target species 
A tolerance trial was conducted with a total of 36 Holstein–Friesian dairy cows allocated to three 
treatment groups (12 cows in each).
28 The cows were fed for 56 days during the early lactation period 
with  a  TMR based (on  a DM  basis) on 50 %  fodder  (grass  silage  and  maize  silage)  and  50 % 
concentrate  (maize,  soybean  meal  and  rapeseed  meal)  that  was  supplemented  with  Ronozyme 
RumiStar at the intended dosage of 0, 600 or 60 000 alpha-amylase KNU/kg TMR DM (analysed 
dosage: below limit of detection, ~2 100 and ~41 000 KNU/kg, respectively). The TMR contained 
29.5 % starch on a DM basis. The general health condition and performance of the animals, as well as 
milk composition, were evaluated. 
There were no significant treatment effects on DM intake, daily milk production, live weight during 
the trial period and milk fat content. However, there was a trend towards a decrease in fat-corrected 
milk production (42.1, 41.7, 40.6 kg/day for the 0, 600 and 60 000 alpha- KNU/kg TMR DM) and 
energy-corrected milk production (42.3, 41.8, 40.9 kg/day) in both groups fed supplemented diets. 
Somatic cell count was significantly lower in the tolerance group than in the negative control. There 
were no health-related incidences associated with the use of alpha-amylase. 
The results of the trial suggested that Ronozyme RumiStar is safe for dairy cows at a maximum level 
of 400 KNU/kg DM of total daily ration when used in a TMR with a starch level below 30 %. 
                                                       
26   Technical dossier/Section II/Annex 2-22. 
27   This section has been edited following the provisions of Article 8(6) and 18 of Regulation (EC) No 1831/2003. 
28   Technical dossier/Section III/Annex 3-1. Ronozyme RumiStar for dairy cows 
 
EFSA Journal 2012;10(7):2777  9 
3.3.  Safety for the consumer 
The studies reported in this section were performed with a liquid non-standardised and non-formulated 
enzyme  concentrate  obtained  from  the  production  strain.  This  was  prepared  following  a  similar 
production process as the one used to produce the enzyme concentrate on a commercial scale and is 
considered appropriate for the conduct of toxicological studies. 
3.3.1.  Genotoxicity studies including mutagenicity 
3.3.1.1.  Bacterial reverse mutation assay 
The enzyme concentrate was examined for mutagenic activity in Salmonella Typhimurium strains 
TA1535, TA1537, TA98, TA100 and in Escherichia coli strains WP2uvrA and WP2uvrApKM101, in 
the presence and absence of metabolic activation (S9-mix).
29 The study was conducted in compliance 
with OECD guideline 471 (rev. 1997)  using the pre-incubation procedure. The test material did not 
induce gene mutations in any bacterial strain, whereas appropriate positive controls, applied with and 
without S9-mix, gave the expected response. 
3.3.1.2.  In vitro mammalian chromosome aberration test 
The enzyme concentrate was tested in an  in vitro chromosome aberration test in cultured human 
lymphocytes  in  the  presence  and  absence  of  metabolic  activation  (S9-mix),  according  to  OECD 
guideline 473 (rev. 1997).
30 Cultures were established from the pooled blood of three male donor s. 
Two independent experiments were performed.   No increase in chromosomal aberration induction 
compared with the untreated control was observed in any experimental condition, whereas appropriate 
positive controls, applied with and without S9-mix, gave the expected response. 
3.3.2.  Subchronic oral toxicity study 
The systemic toxic potential of the enzyme concentrate to rats by oral administration was assessed 
over a period of 13 weeks, in compliance with OECD guideline 408 (rev. 1998).
31 Three groups, each 
comprising 10 male and 10 female Crl:CD
® (SD)IGS BR rats, received the test material by gavage at 
dosages of 1.0, 3.3 or 10.0 mL/kg body weight (bw) per day (equivalent to 16 689 KNU)/kg bw per 
day or 0.07, 0.22 or 0.66 g total organic solid/kg bw per day). The control group received the vehicle 
(purified water) at the same volume/dosage. The highest dosage (10.0 mL/kg bw per day) was the 
maximum practical volume/dosage for repeat dose oral administration. 
During the study, clinical condition, detailed physical and arena observations, sensory reactivity, grip 
strength and motor activity were observed, body weight, food consumption and water consumption 
were recorded, ophthalmic examination was carried out, and haematology, blood chemistry, organ 
weight, gross and histopathology investigations were undertaken. 
Body weight gain, food consumption and food conversion efficiency were unaffected by treatment. No 
effect on organ weights and no significant haematological findings were observed. There were no 
treatment-related ophthalmic findings. No change in the behaviour of the animals was attributable to 
treatment. 
Two females died during the treatment period but these deaths were considered incidental and not 
related to treatment. 
Water consumption was slightly raised in weeks 6 and 12 in females receiving 3.3 mL/kg bw per day 
and in males and females receiving 10 mL/kg bw per day. Blood chemistry during week 13 indicated 
high phosphorus and calcium concentrations in males receiving 10.0 mL/kg bw per day and high 
                                                       
29   Technical dossier/Section III/Annex 3-3. 
30   Technical dossier/Section III/Annex 3-4. 
31   Technical dossier/Section III/Annex 3-5. Ronozyme RumiStar for dairy cows 
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calcium concentrations in males receiving 3.3 mL/kg bw per day. Distension of the caecum (in four 
males and two females) and luminal dilatation of the caecum (in four males and three females) were 
observed in animals given the highest dosage. These changes were attributed to the osmolarity or 
electrolyte composition of the test material at the highest concentration causing adaptive changes in 
the organs in which reabsorption of water takes place (i.e. the kidney and the caecum). 
It is concluded that oral administration of Ronozyme RumiStar to rats at dosages up to 10.0 mL/kg bw 
per day for 13 weeks did not produce any toxicologically significant change. Consequently, the no 
observed adverse effect level of the test article in this study was considered to be 10.0 mL/kg bw per 
day equivalent to 16 689 KNU/kg bw per day Ronozyme RumiStar. 
3.3.3.  Conclusions on the safety for the consumer 
The results of two in vitro genotoxicity studies and a subchronic oral toxicity rat study did not indicate 
any concern for consumer safety arising from the use of Ronozyme RumiStar as a feed additive for 
dairy cows. 
3.4.  Safety for the user 
The studies reported in this section were performed using the same enzyme concentrate used in the 
studies described in section 3.3. 
3.4.1.  Skin and eye irritation 
The enzyme concentrate was tested for acute dermal irritation in three albino rabbits, according to 
OECD guideline 404 (rev. 2002).
32 Individual skin irritation scores were recorded at 1, 24, 48 and 72 
hours after removal of the test substance. At 1 and 24 hours, very slight erythema was observed in all 
three rabbits. At 48 and 72 hours no signs of skin irritation were observed in any animal. Therefore, 
Ronozyme RumiStar is classified as not irritating to (human) skin. 
The eye-irritating properties of enzyme concentrate were assayed in an experiment with three young 
adult male albino rabbits (specific pathogen free bred, New Zealand White albino rabbits), according 
to OECD guideline 405 (rev. 2002).
33 At one hour after treatment, the test article caused slight redness 
of the conjunctivae, with or without slight swelling, in all three rabbits and slight ocular discharge in 
one rabbit. At 24 hours after treatment, slight redness of the conjunctivae, with or without slight 
swelling, was observed in all the three rabbits. All eye effects had completely cleared at 48 hours after 
treatment. Thus, Ronozyme RumiStar is classified as not irritating to (human) eyes. 
3.4.2.  Skin sensitisation 
No data were provided by the applicant. Therefore, the additive is to be considered as a potential skin 
sensitiser. 
3.4.3.  Effects on respiratory system 
The  granular  formulation  of  Ronozyme  RumiStar  (CT)  is  practically  dust  free  according  to  the 
Stauber–Heubach dust test and does not contain particles with a diameter of less than 250 µm and the 
liquid (L) formulation is applied as sprays in closed systems. However, because of the proteinaceous 
nature of the active substance, it should be treated as a potential respiratory sensitiser. 
3.4.4.  Conclusions on the safety for the user 
Ronozyme RumiStar is not considered, based on the result of tests in rabbits, to be irritant to human 
skin  or  eye.  The  additive  is  considered  to  be  a  potential  skin  and  respiratory  sensitiser.  These 
conclusions apply to both forms of the additive. 
                                                       
32   Technical dossier/Section III/Annex 3-8. 
33   Technical dossier/Section III/Annex 3-9. Ronozyme RumiStar for dairy cows 
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3.5.  Safety for the environment 
Neither the production strain nor its recombinant DNA was detectable in the final product. Therefore, 
the  final  product  does  not  trigger  any  environmental  safety  concerns  associated  with  the  genetic 
modification. 
The active substance of Ronozyme RumiStar is a protein and as such will be degraded/inactivated 
during passage through the digestive tract of animals. Therefore, no risks for the environment are 
expected and no further environmental risk assessment is required. 
4.  Efficacy 
Five digestibility and/or production trials were conducted with lactating dairy cows in five different 
locations, two of them outside the EU. 
The first trial was a production and digestibility trial
34 conducted with 36 Holstein–Friesian lactating 
dairy cows (started on day 51 of lactation) divided into three treatment groups (12 cows in each). After 
a 21-day adjustment period, cows were fed for 84 days with TMR containing (on DM basis) 50 % 
fodder (maize silage and alfalfa silage), and 50 % “normal” starch concentrate (starch content 27.1 % 
DM)  or  “reduced” starch concentrate  (starch  content  21.8  %  DM)  without  or  supplemented  with 
Ronozyme RumiStar L at 300 KNU alpha-amylase/kg DM (confirmed by analysis). Dry matter intake 
and milk production were measured daily. The apparent total tract digestibility of DM, organic matter, 
crude protein, neutral detergent fibre (NDF) and starch was measured in a three-day faeces collection 
during  week  8  of  the  trial,  and  indigestible  NDF  was  used  as  an  internal  marker.  The  data  on 
digestibility were not further considered to provide evidence of efficacy. The results on DM intake and 
milk yield are shown in Table 2. The addition of Ronozyme RumiStar to a diet with “reduced” starch 
content resulted in a lower DM intake for the same milk yield, resulting in a better milk to feed ratio in 
dairy cows. 
Table 2:   Effect of Ronozyme RumiStar on the performance parameters in dairy cows 
Diet  Dry matter intake (DMI) 
(kg/day) 
Milk yield 
(kg/day) 
Milk to feed ratio (kg 
milk/kg DMI) 
“Normal” starch   26.7
b  49.8  1.91
ab 
“Reduced” starch   29.1
a  50.9  1.77
b 
“Reduced” starch + Ronozyme 
RumiStar L 300 KNU/kg DM   25.9
b  50.4  1.98
a 
a,b Mean values with different superscripts in the same column are significantly different (P < 0.05). 
The second trial
35 was considered as not adequate for  the assessment of the efficacy for the alpha-
amylase because total tract digestibility of NDF and  acid detergent fibre are  not considered valid 
indicators of alpha-amylase activity. 
In the third trial,
36 three experimental  diets were considered: a  “high”-starch diet (31 %), a “low”-
starch diet (26 %) and a “low”-starch diet supplemented with Ronozyme RumiStar. No significant 
differences resulting from the supplementation with Ronozyme RumiStar were observed. 
The fourth trial was a performance trial
37 in which 70 multiparous, lactating Holstein–Friesian dairy 
cows were allocated to two treatment groups (35 in each). Average initial daily milk production three 
weeks prior to the experimental period (day 71 or 72 in control and experimental groups, respectively) 
was  the  same  in  each  group  (control 42.9  kg;  experimental  42.8 kg).  The  experimental  period 
                                                       
34   Technical dossier/Section IV/Annex 4-4. 
35   Technical dossier/Section IV/Annex 4-8. 
36   Technical dossier/Section IV/Annex 4-9. 
37   Technical dossier/Supplementary information November 2011/Annex 11. Ronozyme RumiStar for dairy cows 
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comprised a 3-week adaptation phase and a 12-week experimental phase. Daily ration contained (on a 
DM basis) 53.3 % fodder (maize silage, alfalfa haylage and grass hay) and 46.7 % concentrate. The 
starch content of the TMR (on a DM basis) was 26.0 %. TMR was given alone or supplemented with 
Ronozyme  RumiStar  CT  at  300 KNU/kg  DM  (confirmed  by  analysis).  Milk  production,  milk 
composition and weight gain of dairy cows were measured. 
The results showed that milk yield was higher in the cows fed the supplemented diet than in cows fed 
the control diet (38.7 ± 7 vs. 37.7 ± 7 kg/day). The differences disappeared when milk production was 
corrected for fat and energy content. In addition, the statistical analysis applied
38 is not considered 
appropriate as all sampling records were treated as independent observations. 
The fifth trial was a performance and digestibility trial
39 in which, initially, 200 multiparous, lactating 
Holstein–Friesian dairy cows were allocated to two treatment groups (100 cows in each). Average 
daily  milk  production  at  the  start  of  the  experiment  was  similar  in  each  group  (control  37.7 kg; 
experimental 36.3 kg). Daily ration contained (on a DM basis) 45.5 % fodder (maize silage, triticale 
silage and grass/ryegrass hay) and 54.5 % concentrate. The starch content of the TMR (on a DM basis) 
was 26.1 %. TMR was given alone or supplemented with Ronozyme RumiStar CT at 300 KNU alpha-
amylase/kg  DM  (confirmed  by  analysis).  Total  tract  digestibility,  using  lignin  as  a  marker,  was 
measured by faecal collections from 16 randomly selected dairy cows. However, these measurements 
are not considered appropriate to the assessment of ruminal starch degradation. Milk production was 
measured daily and milk composition monthly. Results were provided for the cows under study for 12 
weeks. 
The results showed an increase in the milk yield in cows fed Ronozyme Rumistar and under study for 
12 weeks during the first half of the lactation period but not for the whole period. 
4.1.  Conclusions on the efficacy 
From five efficacy studies provided by the applicant, significant positive effects were observed in only 
one  trial in  which an  energy-deficient  diet  was  used.  Thus, no  conclusions can  be drawn on the 
efficacy of Ronozyme RumiStar in dairy cows. 
5.  Post-market monitoring 
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
40  and  Good 
Manufacturing Practice. 
CONCLUSIONS 
The different formulations of the additive are considered to be equivalent, when used at the same dose, 
taking into account the tolerance and efficacy for the target species. 
Since  both  the  production  organism  and  the  level  of  recombinant  DNA  are  below  the  limit  of 
detection, the final product does not trigger a safety concern with regard to the genetic modification. 
Based on the results obtained in the tolerance trial provided by the applicant, it is concluded that 
Ronozyme RumiStar is safe for dairy cows at the maximum proposed dose (400 KNU/kg DM of total 
daily ration) when used in a total mixed ration with a starch level below 30 %. 
                                                       
38   Technical dossier/Supplementary information February 2012/Annex 2. 
39   Technical dossier/Supplementary information November 2011/Annex 12. 
40   Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down 
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Based on the results of two in vitro genotoxicity studies and a subchronic oral toxicity rat study, it is 
concluded that no concerns for consumer safety arise from the use of Ronozyme RumiStar as a feed 
additive for dairy cows. 
Ronozyme RumiStar is not considered, based on the result of tests in rabbits, to be irritant to human 
skin or eye. The additive is considered to be a potential skin and respiratory sensitiser. 
The active substance of Ronozyme RumiStar is a protein and as such will be degraded/inactivated 
during passage through the digestive tract of animals. Therefore, no risks for the environment are 
expected and no further environmental risk assessment is required. 
From five efficacy studies provided by the applicant, significant positive effects were observed in only 
one trial in which an energy deficient diet was used. Therefore, no conclusions can be drawn on the 
efficacy of Ronozyme RumiStar in dairy cows. 
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APPENDIX 
Executive Summary of the Evaluation Report of the European Union Reference Laboratory for 
Feed Additives on the Method(s) of Analysis for Ronozyme RumiStar
41 
Ronozyme RumiStar (CT) (L) is a product for which authorisation as feed additive is sought under the 
category “zootechnical additives”, functional groups 4(a) “digestibility enhancers” according to Annex 
I of Regulation (EC) No 1831/2003. The active agent of Ronozyme RumiStar (CT) (L) is α-amylase 
(E.C. 3.2.1.1), produced by a strain of Bacillus Licheniformis (DSM 21564). The authorisation for 
dairy cows in the lactation period is requested. 
The enzymatic activity of the α-amylase is expressed in “KNU” units. According to the Applicant, one 
KNU is defined as the amount of enzyme that releases 6 μmol p-nitrophenol per minute from 1.86 mM 
ethylidene-G7-p-nitrophenyl-maltoheptaoside at pH 7.0 and 37 °C. 
The product is intended to be marketed in two formulations: (i) as Coated Thermo tolerant granulate 
(CT) with a minimum activity of 160 KNU/g, and (ii) as Aqueous Liquid (L) with a minimum activity 
of 240 KNU/g. The Applicant recommended  α-amylase activity in complete feedingstuffs ranging 
from 300 to 600 KNU/kg. 
For the determination of the activity of α-amylase in the feed additive, premixtures and feedingstuffs, 
the Applicant proposed two single-laboratory validated and further verified colorimetric methods. In 
all methods the activity of the samples is calibrated against reference enzyme standards with known 
activity determined at the definition conditions of the activity unit. 
The  following  performance  characteristics  for  the  determination  of  α-amylase  in  feed  additives, 
premixtures and feedingstuffs, were recalculated by the CRL: 
  for feed additives, a relative standard deviation for repeatability (RSDr) ranging from 1.6 to 
3.3 %, a relative standard deviation for intermediate precision (RSDip) ranging from 3.5 to 
9.1 %; 
  for premixtures, RSDr ranging from 3.9 to 6.5 %, RSDip ranging from 3.6 to 6.5 %; 
  for  feedingstuffs,  RSDr  ranging  from  4.1  to  7.2 %,  RSDip  ranging  from  5.1  to  13.6 %,  a 
recovery  rate  (RRec)  ranging  from  92.6  to  114.4 %,  a  limit  of  detection  (LOD)  and 
quantification (LOQ) of 2 and 7 KNU/kg feedingstuffs, respectively. 
Based on the satisfactory performance characteristics mentioned above, the CRL recommends for 
official control the methods submitted by the applicant for the determination of α-amylase in the feed 
additive, premixtures and feedingstuffs. 
Further  testing  or  validation  of  the  methods to  be performed  through  the consortium  of  National 
Reference Laboratories as specified by article 10 (Commission Regulation (EC) No 378/2005) is not 
considered necessary. 
 
                                                       
41   The full report is available on the EURL website: http://irmm.jrc.ec.europa.eu/SiteCollectionDocuments/FinRep-FAD-
2010-0009.pdf 